Gut compound identified as next target for reducing Alzheimer’s risk
Higher levels of imidazole propionate, a compound produced by some bacteria in the gut, contribute to dementia-related changes in the brain.
Exploring the severity and causes of a debilitating heart condition
Approximately 3 million people in the United States are living with heart failure with preserved ejection fraction, or HFpEF, and their prognosis can be daunting.
Study linking environmental factors and Alzheimer’s disease awarded NIH funding
A nationwide study led by the University of Wisconsin School of Medicine and Public Health that explores the relationship between Alzheimer’s disease, environmental factors and lifetime experiences has been awarded a second round of funding from the National Institutes of Health (NIH).
Fourteen Vilas Awards recognize faculty excellence
Fourteen faculty members in the University of Wisconsin School of Medicine and Public Health received Vilas Awards for the 2025–2026 academic year, the most the school has earned in a single year for at least a decade.
A comprehensive approach to dementia
No cure exists — yet — for Alzheimer’s disease, the brain disorder that slowly destroys memory and thinking skills, along with the ability to complete daily tasks. But dozens of researchers at the University of Wisconsin–Madison, many of them within the UW School of Medicine and Public Health, are working on ways to prevent, slow and cure the disease.
UW–Madison researchers identify therapeutic target for dangerous fungal infections
A multidisciplinary team of researchers at UW–Madison has identified a promising new therapeutic candidate against Candida auris, an emerging fungal pathogen able to resist multiple antifungal drugs and spread rapidly through hospitals and care facilities.
Scientists discover molecular mechanism that could boost calorie burning
GLP-1 drugs have transformed weight loss by suppressing appetite. The other half of the equation — helping the body burn more energy — has received less attention.
Clinical trial tests new cell therapy to manage kidney transplant rejection
A first-of-its-kind clinical trial at the Program for Advanced Cell Therapy will examine a new method to manage kidney rejection following transplant.
Eight researchers transforming colorectal cancer care
March is National Colorectal Cancer Awareness Month, established to raise awareness for a disease that is largely preventable. Colorectal cancer is now the leading cause of cancer death in adults under 50 and the only major cancer where mortality is rising in younger adults, according to a 2026 report from the American Cancer Society.
How AI is advancing medical research
Able to absorb, examine and analyze staggering amounts of data, artificial intelligence (AI) helps medical researchers identify disease patterns and predict patient outcomes.
Cell therapy for Sjögren’s disease earns FDA Fast Track designation
A therapy currently being tested in a clinical trial at the University of Wisconsin School of Medicine and Public Health to treat a common symptom of Sjögren’s disease recently got a boost from the Food and Drug Administration.
UW–Madison and Immuto Scientific to collaborate on novel cancer target discovery
University of Wisconsin–Madison and Immuto Scientific have officially entered into a collaborative agreement to identify disease-specific, novel therapeutic targets in colorectal cancer.